Susanna High

Susanna High is Chief Executive Officer at Paragon. She most recently served as Chief Operating Officer at Dyne Therapeutics, a clinical-stage company focused on developing life-transformative therapies for neuro-muscular diseases leveraging their proprietary antibody-conjugate platform. At Dyne, High contributed to bringing two programs onto their current path for global registrations, helped grow the organization five-fold, and played a role in a very successful IPO and more than $1B in subsequent raises. She previously served as Chief Operating Officer of bluebird bio, where she led the company’s severe genetic disease franchise and established its European organization. Prior to that, High was at Alnylam Pharmaceuticals for 10 years, with roles of increasing responsibility—most recently as Senior Vice President, Strategy and Business Integration, where she helped establish the company’s robust and pioneering RNAi therapeutics platform, grow the organization, and advance multiple products towards registration and launch preparation. Earlier in her career, she held positions in corporate strategy and operations at Millennium Pharmaceuticals (now Takeda Oncology) and in management consulting in the pharmaceutical practice of Accenture. High holds an M.S. in economics and business management from Università Bocconi and an M.B.A. from the MIT Sloan School of Management.